Literature DB >> 21074374

A higher dose of vancomycin in continuous infusion is needed in critically ill patients.

A Jeurissen1, I Sluyts, R Rutsaert.   

Abstract

Compared with intermittent infusion, continuous infusion of vancomycin is cheaper and logistically more convenient, achieves target concentrations faster, results in less variability in serum vancomycin concentrations, requires less therapeutic drug monitoring and causes less nephrotoxicity. Given that critically ill patients may develop very large volumes of distribution as well as supranormal drug clearance, in this study it was shown, despite the limited number of patients studied, that to achieve a target plateau concentration of 25mg/L a daily dose of 3000 mg of vancomycin in continuous infusion is needed following an appropriate loading dose.
Copyright © 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21074374     DOI: 10.1016/j.ijantimicag.2010.09.004

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  19 in total

Review 1.  Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review.

Authors:  Sepideh Elyasi; Hossein Khalili; Simin Dashti-Khavidaki; Amirhooshang Mohammadpour
Journal:  Eur J Clin Pharmacol       Date:  2012-03-13       Impact factor: 2.953

2.  Appropriate antibiotic dosage levels in the treatment of severe sepsis and septic shock.

Authors:  Fabio Silvio Taccone; Maya Hites; Marjorie Beumier; Sabino Scolletta; Frédérique Jacobs
Journal:  Curr Infect Dis Rep       Date:  2011-10       Impact factor: 3.725

Review 3.  Optimizing the Clinical Use of Vancomycin.

Authors:  Rocío Álvarez; Luis E López Cortés; José Molina; José M Cisneros; Jerónimo Pachón
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

4.  Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens.

Authors:  Jason A Roberts; Fabio Silvio Taccone; Andrew A Udy; Jean-Louis Vincent; Frédérique Jacobs; Jeffrey Lipman
Journal:  Antimicrob Agents Chemother       Date:  2011-03-14       Impact factor: 5.191

5.  Vancomycin Use in a Paediatric Intensive Care Unit of a Tertiary Care Hospital.

Authors:  Kannan Sridharan; Amal Al-Daylami; Reema Ajjawi; Husain Am Al Ajooz
Journal:  Paediatr Drugs       Date:  2019-08       Impact factor: 3.022

6.  Influence of Mechanical Ventilation on the Pharmacokinetics of Vancomycin Administered by Continuous Infusion in Critically Ill Patients.

Authors:  Susanna Edith Medellín-Garibay; Silvia Romano-Moreno; Pilar Tejedor-Prado; Noelia Rubio-Álvaro; Aida Rueda-Naharro; Miguel Angel Blasco-Navalpotro; Benito García; Emilia Barcia
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

Review 7.  Vancomycin Dosing and Monitoring: Critical Evaluation of the Current Practice.

Authors:  Fawzy Elbarbry
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-06       Impact factor: 2.441

Review 8.  Vancomycin dosing nomograms targeting high serum trough levels in different populations: pros and cons.

Authors:  Sepideh Elyasi; Hossein Khalili
Journal:  Eur J Clin Pharmacol       Date:  2016-04-27       Impact factor: 2.953

9.  Development of acute kidney injury during continuous infusion of vancomycin in septic patients.

Authors:  S Cianferoni; A Devigili; E Ocampos-Martinez; L Penaccini; S Scolletta; A Abdelhadii; D De Backer; M Beumier; F Jacobs; J-L Vincent; F S Taccone
Journal:  Infection       Date:  2013-04-10       Impact factor: 3.553

10.  New Regimen for Continuous Infusion of Vancomycin in Critically Ill Patients.

Authors:  Stefano Cristallini; Maya Hites; Hakim Kabtouri; Jason A Roberts; Marjorie Beumier; Frederic Cotton; Jeffrey Lipman; Frédérique Jacobs; Jean-Louis Vincent; Jacques Creteur; Fabio Silvio Taccone
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.